---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-039772"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T11:46:08.986241+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AlloVir reports FY2022 net loss of $168.7M and positive Phase 2 posoleucel data in kidney transplant

## Summary
- FY2022 net loss $168.7M ($2.20/share); R&D spend $118.9M; cash & securities $233.8M as of Dec 31, 2022.
- 2023 operating expense guidance of $150-170M (excl. non-cash); Phase 3 enrollment completion expected by end of 2023 with 2024 data.
- Phase 2 study: posoleucel achieved ≥1-log viral load reduction in 39% vs 14% placebo; biweekly dosing 50%.
- In high viral load (≥10,000 copies/mL): 69% posoleucel vs 25% placebo achieved ≥1-log reduction; 75% for biweekly dosing.
- Posoleucel well tolerated with balanced safety; no GVHD, cytokine release syndrome, or treatment-related acute rejection.

## SEC filing metadata
- accession: 0001193125-23-039772
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312523039772/0001193125-23-039772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312523039772/d468482d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-039772
- JSON: https://secwatch.observer/filing/0001193125-23-039772.json
- Plain text: https://secwatch.observer/filing/0001193125-23-039772.txt

## Key facts
- Earnings Releases
  Kalaris Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 15, 2023, AlloVir, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523039772/0001193125-23-039772-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.